Article

New vision center in Philadelphia

The Wills Eye Institute and Thomas Jefferson University have created the Wills Vision Research Center at Jefferson.

Philadelphia-The Wills Eye Institute and Thomas Jefferson University have created the Wills Vision Research Center at Jefferson.

The center will use a multidisciplinary team approach that will draw on knowledge and clinical expertise in 15 fields, among them ophthalmology, oncology, pathology, neurology, and endocrinology. One goal will be the fostering of regional, national, and global collaborations.

Julia A. Haller, MD, and A. Sue Menko, PhD, will direct the new center. Dr. Haller is the ophthalmologist-in-chief at Wills Eye Institute and a professor and chairwoman of the department of ophthalmology at Jefferson Medical College of Thomas Jefferson University. Dr. Menko is a professor of pathology, anatomy, and cell biology at Jefferson Medical College.

“The primary focus of this new initiative is on translational research and studies that will have a major impact on improving vision health,” said Dr. Haller, a member of the Ophthalmology Times Editorial Advisory Board.

Research projects already in development include understanding the genetics of congenital abnormalities; preventing neurodegenerative diseases such as age-related macular degeneration and Parkinson’s disease; new treatments for visual system cancers such as retinoblastoma and uveal melanoma; the connection between low vision and depression, especially in the elderly; and diabetic retinopathy.

“A major objective at Thomas Jefferson University over the next several years is to increase our portfolio of programmatic research initiatives,” said Leonard Freedman, PhD, vice dean for research, Jefferson Medical College. “The depth and breadth of the Wills Eye/Jefferson Vision Center is exactly the kind of multidisciplinary approach we believe represents the future of biomedical research.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.